← All countries · Americas
83%
MCV1
2025 · WHO/UNICEF estimate
93%
DTP3
2025 · WHO/UNICEF estimate
93%
IPV complete
2025 · WHO/UNICEF estimate
86%
HepB3
2025 · WHO/UNICEF estimate
0
Measles cases
2025 reported
0
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | —% · Administrative (country-reported) | — | too few points | no data |
| DTP1First dose of diphtheria-tetanus-pertussis | 93%2025 · WHO/UNICEF estimate | 82.5% | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 93%2025 · WHO/UNICEF estimate | 83.1% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 93%2025 · WHO/UNICEF estimate | 82.5% | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 93%2025 · WHO/UNICEF estimate | 84.7% | C · weak | |
| MCV1First dose of measles-containing vaccine | 83%2025 · WHO/UNICEF estimate | 83.0% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 67%2025 · WHO/UNICEF estimate | 89.3% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 83%2025 · WHO/UNICEF estimate | 83.0% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 86%2025 · WHO/UNICEF estimate | 83.1% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 95%2025 · WHO/UNICEF estimate | 94.0% | B · good | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 93%2025 · WHO/UNICEF estimate | 83.1% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 88.8%2025 · Administrative (country-reported) | 88.8% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 0%2025 · Administrative (country-reported) | 0% | D · poor | |
| RotaCRotavirus vaccine, complete series | 86.0%2025 · Administrative (country-reported) | 86.0% | D · poor | |
| Yellow feverYellow fever vaccine (countries at risk) | 0%2015 · Administrative (country-reported) | 0% | too few points | D · poor |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | 0%2015 · Administrative (country-reported) | 0% | too few points | D · poor |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 3%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 3%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 1%2025 · WHO/UNICEF estimate | — | too few points | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Pertussis (whooping cough) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 02025 | 0per 1,000,000 <15 population | C · weak | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Invasive meningococcal disease all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | D · poor | |
| Typhoid all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak |
National schedule (latest WHO listing)
Show the schedule (53 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | 1st contact | Travellers | Travelers |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 5 | Y4 | General/routine | 4-5 Yr old |
| DTWPDTwP (Whole cell) vaccine | 4 | M18 | General/routine | M18 old |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | W6 | General/routine | 6W to 6M |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | M4 | General/routine | 6W to 6M |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | M6 | General/routine | 6W to 6M |
| DTWPHIBHEPBIPVDTwP-Hib-HepB-IPV (Whole cell) vaccine | 1 | W8 | General/routine | 6-18M |
| DTWPHIBHEPBIPVDTwP-Hib-HepB-IPV (Whole cell) vaccine | 2 | M4 | General/routine | 6-18M |
| DTWPHIBHEPBIPVDTwP-Hib-HepB-IPV (Whole cell) vaccine | 3 | M6 | General/routine | 6-18M |
| DTWPHIBHEPBIPVDTwP-Hib-HepB-IPV (Whole cell) vaccine | 4 | M18 | General/routine | 6-18M |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Health workers | high risk groups, health workers and sanitation workers |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Risk group(s) | high risk groups, health workers and sanitation workers |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Health workers | high risk groups, health workers and sanitation workers |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Risk group(s) | high risk groups, health workers and sanitation workers |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Health workers | high risk groups, health workers and sanitation workers |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Risk group(s) | high risk groups, health workers and sanitation workers |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | Live birth |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y9-Y14 | HPV administered to females and males | Target-9-14 yr Girls/Boys- Doses- 1 (1 dose commenced in 2023) |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | M6-Y9 |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | W6-W8 | General/routine | 8W-18M |
| IPVIPV (Inactivated polio vaccine) | 2 | M4 | General/routine | 8W-18M |
| IPVIPV (Inactivated polio vaccine) | 3 | M6 | General/routine | 8W-18M |
| IPVIPV (Inactivated polio vaccine) | 4 | M18 | General/routine | 8W-18M |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | 1yr old and 18 month old |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M18 | General/routine | 1yr old and 18 month old |
| OPVOPV (Oral polio vaccine) | 2 | M4 | General/routine | M4 to 14yrs old |
| OPVOPV (Oral polio vaccine) | 4 | M18 | General/routine | M4 to 14yrs old |
| OPVOPV (Oral polio vaccine) | 5 | Y4-Y5 | General/routine | M4 to 14yrs old |
| OPVOPV (Oral polio vaccine) | 6 | Y14-Y15 | General/routine | M4 to 14yrs old |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 1 | W8 | General/routine | 8W-M12 |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 2 | M4 | General/routine | 8W-M12 |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 3 | M12 | General/routine | 8W-M12 |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | W8 | General/routine | W8-M6 |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | M4 | General/routine | W8-M6 |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | M6 | General/routine | W8-M6 |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Pregnant women | Given to adults and pregnant women as needed based on vaccination history |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Risk group(s) | Given to adults and pregnant women as needed based on vaccination history |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Pregnant women | Given to adults and pregnant women as needed based on vaccination history |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Risk group(s) | Given to adults and pregnant women as needed based on vaccination history |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Pregnant women | Given to adults and pregnant women as needed based on vaccination history |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Risk group(s) | Given to adults and pregnant women as needed based on vaccination history |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | Y4 | General/routine | 14yrs old |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y14 | General/routine | 14yrs old |
| VARICELLAVaricella vaccine | 1 | 1st contact | Risk group(s) | Contacts to cases/ in outbreaks and travel/study purposes, personal choice |
| VARICELLAVaricella vaccine | 1 | 1st contact | Travellers | Contacts to cases/ in outbreaks and travel/study purposes, personal choice |
| VARICELLAVaricella vaccine | 2 | +M1 | Risk group(s) | Contacts to cases/ in outbreaks and travel/study purposes, personal choice |
| VARICELLAVaricella vaccine | 2 | +M1 | Travellers | Contacts to cases/ in outbreaks and travel/study purposes, personal choice |
| YFYF (Yellow fever) vaccine | 1 | 1st contact | Travellers | travellers, adults and children from 6M of age - information will be based on manufacture leaflet |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.